Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB.
Both clinical and preclinical research have shown that stress can potentiate drug use; however, the underlying mechanisms of this interaction are unknown. Previously, we have shown that a single exposure to forced swim (FS) reinstates extinguished conditioned place preference (CPP) to cocaine and that cAMP response element binding protein (CREB) is necessary for this response. CREB can be activated by corticotropin releasing factor (CRF) receptor type 1 (CRF(R1)) binding, which mediates neuroendocrine and behavioral responses to stress as well as to drugs of abuse. The present experiments investigate whether changes in cocaine reward elicited by previous exposure to stress are mediated by CREB and/or CRF(R1). Chronic exposure to FS in advance of conditioning enhances cocaine CPP in wild-type mice, but this is blocked in CREB-deficient mice. In addition, pretreatment with the CRF(R1) antagonist, antalarmin, before FS exposure blocks this stress-induced enhancement of cocaine CPP. Furthermore, FS-induced increase in phosphorylated CREB (pCREB), specifically in the lateral septum (LS) and nucleus accumbens (NAc) is also blocked by antalarmin. Taken together, these studies suggest that both CREB and CRF(R1) activation are necessary for stress-induced potentiation of drug reward.
Kreibich
Arati S
AS
Department of Pharmacology, University of Pennsylvania, Philadelphia, PA 19104-3403, USA.
Briand
Lisa
L
Cleck
Jessica N
JN
Ecke
Laurel
L
Rice
Kenner C
KC
Blendy
Julie A
JA
D000818:Animals; D003042:Cocaine / Q000494:pharmacology*; D003214:Conditioning, Classical / Q000187:drug effects / Q000502:physiology; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics / Q000378:metabolism*; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology*; D051379:Mice; D018345:Mice, Knockout; D009714:Nucleus Accumbens / Q000187:drug effects / Q000503:physiopathology; D010766:Phosphorylation / Q000187:drug effects / Q000502:physiology; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D011758:Pyrroles / Q000008:administration & dosage / Q000494:pharmacology; D018019:Receptors, Corticotropin-Releasing Hormone / Q000037:antagonists & inhibitors / Q000378:metabolism*; D012201:Reward; D020665:Septum of Brain / Q000187:drug effects / Q000503:physiopathology; D013028:Space Perception / Q000187:drug effects / Q000502:physiology; D013315:Stress, Psychological / Q000503:physiopathology*; D013550:Swimming; D013997:Time Factors; D000099052:CRF Receptor, Type 1
C492004:Creb1 protein, mouse; D017362:Cyclic AMP Response Element-Binding Protein; D018765:Dopamine Uptake Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; D018019:Receptors, Corticotropin-Releasing Hormone; C103016:antalarmin; D000099052:CRF Receptor, Type 1; D003042:Cocaine
Neuroendocrinology. 1996 Nov;64(5):337-48
8930934
Psychopharmacology (Berl). 2003 Nov;170(2):124-31
12845410
Psychopharmacology (Berl). 1995 Jan;117(1):102-9
7724693
J Neurosci. 1992 Oct;12(10):4112-21
1403102
J Neurosci. 2008 Jul 9;28(28):7184-92
18614688
J Neurosci. 2008 Oct 29;28(44):11401-8
18971482
Psychopharmacology (Berl). 2005 Jul;180(2):215-23
15696320
Addict Behav. 1988;13(2):191-5
3369329
Psychopharmacology (Berl). 1996 Dec;128(3):256-64
8972545
Am J Psychiatry. 2007 Aug;164(8):1149-59
17671276
J Neurosci. 1993 Sep;13(9):3932-43
8366353
Psychopharmacology (Berl). 1994 Apr;114(3):523-7
7855213
Endocrinology. 1996 Dec;137(12):5747-50
8940412
Neuroimage. 2008 Jan 1;39(1):538-47
17904386
Curr Psychiatry Rep. 2007 Oct;9(5):388-95
17915078
Neuropharmacology. 2009;56 Suppl 1:122-32
18675281
Psychoneuroendocrinology. 1997 May;22(4):237-59
9226728
Ann N Y Acad Sci. 2002 Jun;966:119-30
12114266
Science. 1998 Dec 18;282(5397):2272-5
9856954
J Neuroendocrinol. 2002 Jul;14(7):587-92
12121497
J Health Soc Behav. 1986 Mar;27(1):44-61
3486897
J Neurosci. 2001 Dec 1;21(23):9438-44
11717377
Brain Res. 1993 Apr 16;608(2):216-22
8495356
J Neurosci. 2009 Feb 11;29(6):1855-9
19211892
Brain Res Brain Res Rev. 2004 Aug;46(1):71-117
15297155
J Neurosci. 2005 Jan 19;25(3):577-83
15659593
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11435-40
12165570
Brain Res. 1990 Oct 29;531(1-2):322-8
1963104
J Pharmacol Exp Ther. 1997 Aug;282(2):967-76
9262365
Brain Res. 1995 Nov 6;698(1-2):46-52
8581502
Neuropsychopharmacology. 2000 Nov;23(5):577-86
11027923
Brain Res. 1990 Apr 23;514(1):22-6
2357527
J Neurosci. 2004 Jul 28;24(30):6686-92
15282271
Psychopharmacology (Berl). 1994 Feb;114(1):63-70
7846208
Neuropsychopharmacology. 2004 Jun;29(6):1122-33
15029152
J Neurosci. 2001 Sep 15;21(18):7397-403
11549750
Pharmacol Rev. 2001 Jun;53(2):209-43
11356984
J Stud Alcohol. 1992 Jul;53(4):357-63
1619930
Neurosci Biobehav Rev. 2004 Jan;27(8):765-76
15019426
Eur J Neurosci. 1999 Mar;11(3):997-1002
10103093
J Neurosci. 2002 Apr 15;22(8):3262-8
11943827
J Neurochem. 2003 Mar;84(6):1378-86
12614338
Neuroscience. 2006 Nov 3;142(4):1281-92
16938401
Behav Pharmacol. 1994 Jun;5(3):360-364
11224287
J Neurosci. 2003 Jul 2;23(13):5674-83
12843270
Eur J Neurosci. 2000 Jun;12(6):2097-106
10886349
Trends Pharmacol Sci. 1998 Feb;19(2):67-74
9550944
Psychopharmacology (Berl). 1979;66(1):87-91
120547
Neuron. 2005 Jun 16;46(6):933-43
15953421
Neuroscience. 2003;118(2):297-310
12699766
Drug Alcohol Depend. 1998 Dec 1;53(1):67-77
10933341
Brain Behav Evol. 1989;33(2-3):157-61
2758295
J Neurosci. 2002 Aug 15;22(16):7308-20
12177226
Science. 1981 Sep 18;213(4514):1394-7
6267699